This website is intended for US Healthcare Professionals.

CONTact Your MSL
Back to Congresses

SABCS

  • December 5 -
  • 9, 2023
  •  |
  • San Antonio, TX

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

Presentation
Vepdegestrant, a PROteolysis Targeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Palbociclib in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase 1b Cohort
EP Hamilton et al.
View Material
View Summary
Poster
Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER–Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer
SA Hurvitz et al.
View Material
View Summary
Poster
TACTIVE-U: Phase 1b/2 Umbrella Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Combined With Other Anticancer Treatments in ER-Positive Advanced or Metastatic Breast Cancer
C Isaacs et al.
View Material
View Summary
Poster
VERITAC-2: A Phase 3 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER Positive/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Advanced Breast Cancer
M Campone et al.
View Material
View Summary
Poster
VERITAC-3: A Randomized Phase 3 Study, With a Lead in, of First Line Vepdegestrant + Palbociclib vs Letrozole + Palbociclib in Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer
SA Wander et al.
View Material
View Summary
Poster
Leveraging a Pharmacokinetic/Pharmacodynamic (PK/PD) Model to Guide Dose Optimization of Palbociclib in Combination With Vepdegestrant
B Jermain et al.
View Material

Arvinas Oncology Medical

You are now leaving arvinasoncologymedical.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

YES, I AM AN HCP

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.

I AM NOT AN HCP